Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новый оригинальный антигистаминный препарат биластин в лечении аллергического ринита
Новый оригинальный антигистаминный препарат биластин в лечении аллергического ринита
Кривопалов А.А., Коноплев О.И., Шервашидзе С.В., Шаталов В.А. Новый оригинальный антигистаминный препарат биластин в лечении аллергического ринита. Consilium Medicum. 2017; 19 (3): 87–90.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Аллергический ринит – одно из наиболее широко распространенных заболеваний человека, связанное с серьезными ограничениями как в физических, психологических, так и социальных аспектах жизни, являющееся причиной снижения качества жизни. Препаратами 1-го выбора у пациентов с симптомами сезонного и круглогодичного аллергического ринита, как интермиттирующего, так и персистирующего течения, являются антигистаминные препараты II поколения, обладающие высоким сродством к H1-рецепторам. В статье представлен обзор нового представителя указанной группы лекарственных средств – препарата Никсар® (биластин).
Ключевые слова: аллергический ринит, риноконъюнктивит, антигистаминные препараты, биластин.
Ключевые слова: аллергический ринит, риноконъюнктивит, антигистаминные препараты, биластин.
________________________________________________
Allergic rhinitisis one of the most common human diseases associated with severe restrictions on physical, psychological and social aspects of life and is the cause of the reduction in quality of life.The drug of first choice in patients with symptoms of seasonal and year-roundallergic rhinitis, associated as well with intermittent and persistent currents is the second-generation antihistamines having a higher affinity for H1-receptors. The article deals with the overview of new drug among the second-generation antihistamines – bilastine (Nixar®).
Key words: allergic rhinitis, rhinoconjunctivitis, antihistamines, bilastine.
Key words: allergic rhinitis, rhinoconjunctivitis, antihistamines, bilastine.
Полный текст
Список литературы
1. Lucero ML, Gonzalo A, Mumford R et al. An overview of bilastine metabolism during preclinical investigations. Drug Chem Toxicol 2012; 35 (Suppl. l): 18–24.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
3. Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно-сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: с. 157–71. / Vasilevskii I.V. Reabilitatsiia detei i podrostkov s zabolevaniiami organov dykhaniia, pishchevareniia, pochek, serdechno-sosudistoi sistemy i allergicheskimi bolezniami v usloviiakh polikliniki. Minsk: BelMAPO, 2007: s. 157–71. [in Russian]
4. Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и др. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А.Горячкиной и Е.П.Кашкина. М.: Миклош, 2009. / Goriachkina L.A., Kashkin E.P., Terekhova E.P. i dr. Klinicheskaia allergologiia i immunologiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. L.A.Goriachkinoi i E.P.Kashkina. M.: Miklosh, 2009. [in Russian]
5. Graff C, Struijk JJ, Kanters JK et al. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339–51.
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1988; 94: 187–91.
7. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121–45.
8. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–35.
9. Sadaba B, Gomez-Guiu A, Azanza JR et al. Oral availability of bilastine. Clin Drug Invest 2013; 33: 375–81.
10. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp Opin Drug Saf 2011; 10 (5): 779–93.
11. Corcostegui R, Labeaga L, Innerarity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D 2006; 7: 219–31.
12. Sastre J, Mullol J, Valero A. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
13. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516–28.
14. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy 2014; 4: 142–8.
15. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900.
16. Dykewicz MS, Fineman S, Skoner DP. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
3. Vasilevskii I.V. Reabilitatsiia detei i podrostkov s zabolevaniiami organov dykhaniia, pishchevareniia, pochek, serdechno-sosudistoi sistemy i allergicheskimi bolezniami v usloviiakh polikliniki. Minsk: BelMAPO, 2007: s. 157–71. [in Russian]
4. Goriachkina L.A., Kashkin E.P., Terekhova E.P. i dr. Klinicheskaia allergologiia i immunologiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. L.A.Goriachkinoi i E.P.Kashkina. M.: Miklosh, 2009. [in Russian]
5. Graff C, Struijk JJ, Kanters JK et al. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339–51.
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1988; 94: 187–91.
7. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121–45.
8. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–35.
9. Sadaba B, Gomez-Guiu A, Azanza JR et al. Oral availability of bilastine. Clin Drug Invest 2013; 33: 375–81.
10. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp Opin Drug Saf 2011; 10 (5): 779–93.
11. Corcostegui R, Labeaga L, Innerarity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D 2006; 7: 219–31.
12. Sastre J, Mullol J, Valero A. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
13. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516–28.
14. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy 2014; 4: 142–8.
15. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900.
16. Dykewicz MS, Fineman S, Skoner DP. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518.
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
3. Василевский И.В. Реабилитация детей и подростков с заболеваниями органов дыхания, пищеварения, почек, сердечно-сосудистой системы и аллергическими болезнями в условиях поликлиники. Минск: БелМАПО, 2007: с. 157–71. / Vasilevskii I.V. Reabilitatsiia detei i podrostkov s zabolevaniiami organov dykhaniia, pishchevareniia, pochek, serdechno-sosudistoi sistemy i allergicheskimi bolezniami v usloviiakh polikliniki. Minsk: BelMAPO, 2007: s. 157–71. [in Russian]
4. Горячкина Л.А., Кашкин Е.П., Терехова Е.П. и др. Клиническая аллергология и иммунология: руководство для практикующих врачей. Под ред. Л.А.Горячкиной и Е.П.Кашкина. М.: Миклош, 2009. / Goriachkina L.A., Kashkin E.P., Terekhova E.P. i dr. Klinicheskaia allergologiia i immunologiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. L.A.Goriachkinoi i E.P.Kashkina. M.: Miklosh, 2009. [in Russian]
5. Graff C, Struijk JJ, Kanters JK et al. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339–51.
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1988; 94: 187–91.
7. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121–45.
8. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–35.
9. Sadaba B, Gomez-Guiu A, Azanza JR et al. Oral availability of bilastine. Clin Drug Invest 2013; 33: 375–81.
10. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp Opin Drug Saf 2011; 10 (5): 779–93.
11. Corcostegui R, Labeaga L, Innerarity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D 2006; 7: 219–31.
12. Sastre J, Mullol J, Valero A. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
13. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516–28.
14. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy 2014; 4: 142–8.
15. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900.
16. Dykewicz MS, Fineman S, Skoner DP. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518.
________________________________________________
2. Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA²LEN and AllerGen. Allergy 2008; 63 (Suppl. 86): 8–160.
3. Vasilevskii I.V. Reabilitatsiia detei i podrostkov s zabolevaniiami organov dykhaniia, pishchevareniia, pochek, serdechno-sosudistoi sistemy i allergicheskimi bolezniami v usloviiakh polikliniki. Minsk: BelMAPO, 2007: s. 157–71. [in Russian]
4. Goriachkina L.A., Kashkin E.P., Terekhova E.P. i dr. Klinicheskaia allergologiia i immunologiia: rukovodstvo dlia praktikuiushchikh vrachei. Pod red. L.A.Goriachkinoi i E.P.Kashkina. M.: Miklosh, 2009. [in Russian]
5. Graff C, Struijk JJ, Kanters JK et al. Effects ofbilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clin Drug Invest 2012; 32: 339–51.
6. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1988; 94: 187–91.
7. Kellaway CH, Trethewie ER. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940; 30: 121–45.
8. Brocklehurst W. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416–35.
9. Sadaba B, Gomez-Guiu A, Azanza JR et al. Oral availability of bilastine. Clin Drug Invest 2013; 33: 375–81.
10. Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Exp Opin Drug Saf 2011; 10 (5): 779–93.
11. Corcostegui R, Labeaga L, Innerarity A et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine HI receptor antagonist. Drugs R D 2006; 7: 219–31.
12. Sastre J, Mullol J, Valero A. Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012; 28: 121–30.
13. Zuberbier T, Oanta A, Bogacka E. Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg forthe treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516–28.
14. Prepageran N, Wangde Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic lhinosinusitis: a Malaysian perspective. Asia Рас Allergy 2014; 4: 142–8.
15. Tashiro M, Sakurada Y, Iwabuchi K et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine HI-receptor occupancy using 1 lC-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890–900.
16. Dykewicz MS, Fineman S, Skoner DP. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478–518.
Авторы
А.А.Кривопалов*, О.И.Коноплев, С.В.Шервашидзе, В.А.Шаталов
ФГБУ «Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи» Минздрава России. 190013, Россия, Санкт-Петербург, ул. Бронницкая, д. 9
*krivopalоv@list.ru
ФГБУ «Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи» Минздрава России. 190013, Россия, Санкт-Петербург, ул. Бронницкая, д. 9
*krivopalоv@list.ru
________________________________________________
A.A.Krivopalov*, O.I.Konoplev, S.V.Shervashidze, V.A.Shatalov
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation. 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
*krivopalоv@list.ru
Saint Petersburg Research Institute of Ear, Nose, Throat and Speech of the Ministry of Health of the Russian Federation. 190013, Russian Federation, Saint Petersburg, ul. Bronnitskaya, d. 9
*krivopalоv@list.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.